close-icon

Welcome

Connect with the future of healthcare

With thousands of clients (B2C and B2B) in more than 100 countries , at 24Genetics we have possibly the most comprehensive DNA tests on the market and we are pioneers in Subscription Services that integrate Genetics with Artificial Intelligence through services such as our AI Nutritional Assistant.

Since 2021, we have prepared the company to scale, multiplying our turnover X3 and obtaining profits of +25% in 2023. With this new round, we hope to take the definitive leap that will allow us to position ourselves in a good exit position.

68
remaining days
119 investors
Investment achieved
313.560€
Target
500.000€
Invested
62.7%
62.7% INVESTED
Maturity

Profits/dividends

Premoney valuation

14.000.000

Estimated exit

2027

Sector

Biotechnology

Equity offered

15%

Minimum investment

500

EN based flag
Equity L
Tax deduction
close modal

Share this project on your website.

Copy and paste the following code into your content.

Overview: 24Genetics

Valuation 14.000.000
Estimated return x10
% Offered 15%
Estimated exit 2027

We have created new services that combine genetics and artificial intelligence; our AI nutritional assistant is now a reality.

Since 2021 we have prepared the company to scale, multiplying our turnover X3 and obtaining profits of +25% in 2023.

We want to add value to society by facilitating global access to genetic testing and, therefore, to personalized medicine.

Genetics is revolutionizing health and wellness, Artificial Intelligence is transforming everything, and 24Genetics is at the right time and place, leading this great change.

The combination of genetics and artificial intelligence is revolutionizing the world of health and well-being. 24Genetics is a pioneer in this new reality.

Since its inception in 2019, 24Genetics has developed what are currently the most comprehensive genetic tests on the market : health, nutrigenetics, sport, skin care, pharmacogenetics, personality, ancestry and oral microbiome. We have tens of thousands of customers in more than 100 countries and have generated a broad sales channel through distributors on five continents ( the B2B channel is 33% of our sales and is constantly growing).

Genetics is radically changing the way we manage our health and well-being: in countries with the most advanced preventive medicine, the use of genetics is already a reality. On the other hand, artificial intelligence is bringing about a paradigm shift in practically all sectors in which technology is involved.

At 24Genetics, we continue to innovate: the combination of AI and DNA is now a reality in our company. We have launched a powerful AI nutritional assistant on the market, which, taking into account a person’s genetic predispositions, their goals and their individual preferences, is capable of designing a diet with a level of personalization unknown until now. But it doesn’t stop there.

It also helps you make better decisions on a daily basis, such as choosing a dish in a restaurant, creating a shopping list or providing information on the calories and macronutrients of a dish by simply sending a photo via WhatsApp.

And this is just the beginning, because we are already working on other projects that integrate AI and genetics, which will revolutionize the wellness sector, enabling a new subscription business model .

In short: genetics is radically changing the way we manage our health and well-being, Artificial Intelligence is revolutionizing everything, and we are in the right place at the right time, doing what needs to be done in a market that is constantly growing.

We hope you will join us on this new stage of our journey.

Why is Capital Cell investing in this company?

24Genetics is a leader in the personal genomics sector in Europe, with constant growth and a significant international reach. Since its last round of financing in 2021, it has tripled revenues, demonstrating the scalability and profitability of its model. With clients in more than 100 countries and a portfolio covering eight key areas - from health and sport to pharmacogenetics and microbiome - 24Genetics has integrated genetics and artificial intelligence to create personalized solutions. This approach, which is emerging as the new standard in health and well-being, allows users to identify predispositions and design optimized programs to improve their quality of life. The recent shift to a subscription-based business model, supported by artificial intelligence services, reinforces recurring revenue, complementing its strong B2B base. With this round, they seek to accelerate product innovation and boost sales and marketing, consolidating their position as leaders in a sector that grows at 20% annually. 24Genetics represents a unique investment opportunity, combining social impact, a proven profitability model and a clear vision for the future of global expansion.

Minimum investment: 500
Type of exit expected: Sale of the company
Drag-along rights
Tag-along rights
Tax deductions
Main risks

24Genetics faces a highly competitive market, with numerous players offering similar genetic tests, which could put pressure on margins and make differentiation difficult. In addition, although they already have a presence in more than 100 countries, expanding into new markets brings regulatory and marketing challenges that could slow their growth.